Hememics Biotechnologies

Hememics Biotechnologies is a private, pre-revenue diagnostics company founded in 2015 and headquartered in Rockville, Maryland. The company has developed the FAST™ technology platform, which leverages functionalized graphene biochips and a proprietary reader to perform multiplexed antibody-antigen binding assays in under an hour. Its value proposition targets the research and biologics development markets by offering a rapid, low-cost, and user-friendly alternative to time-consuming and subjective traditional immunoassays. Leadership comprises a small, experienced team with backgrounds in entrepreneurship, biomedical research, and finance.

FAST™ (Functionalized Analyte Screening Technology) using monolayer graphene biochips and a proprietary electronic reader for rapid, multiplexed immunoassays.

Hememics competes with established immunoassay giants (e.g., Thermo Fisher, Bio-Rad) and numerous ELISA kit vendors in the research market. It also faces potential competition from other companies developing novel, rapid biosensing platforms using different technologies (e.g., lateral flow, microfluidics, other nanomaterials).